Table 3 Effects of Dexmedetomidine on Arterial Pressure, Heart Rate, and Respiratory Parameters
From: Perioperative Dexmedetomidine for outpatient cataract surgery: a systematic review
Study | Dexmedetomidine | Other Treatment Group(s) | Arterial Pressure | Heart Rate | Respiratory Parameters | |
|---|---|---|---|---|---|---|
Bolus | Continuous infusion | |||||
Abdalla [23] | + | + | saline | Decreased SBPa at 30 mins after starting infusion [SBP mean (SDb): 136.10 (15.24) vs 150.15 (21.73) mm Hgc, P = 0.043] | Decreased at 30 mins after starting infusion [HRd mean (SD): 66.90 (5.42) vs 81.20 (7.83), P = 0.041] Decreased at 60 mins after starting infusion [HR mean (SD): 63.60 (4.55) vs 79.75 (7.83), P = 0.049] | – |
Alhashemi [12] | + | + | midazolam | Decreased MAPe [MAP (SEf): 86 (3) vs 102 (3) mm Hg, P < 0.05] | Decreased [HR (SE): 65 (2) vs 72 (2) bpm, P < 0.05] | No statistically significant differences reported |
Altiparmak [24] | – | + | remifentanil | No statistically significant differences in MAP between groups | No statistically significant differences | Increased oxygen saturation at 1 min [mean SpO2g (SD): 94.97 (2.0) vs 93.56 (2.69), P = 0.014], 5 mins [mean SpO2 (SD): 95.50 vs 92.84 (4.56), P = 0.001], 10 mins [mean SpO2 (SD): 95.52 (2.57) vs 92.65 (3.31), P = 0.000], 15 mins [96.02 (2.27) vs 93.34 (4.08), P = 0.001], and 20 mins [mean SpO2 (SD): 95.95 (2.43) vs 92.78 (4.15), P = 0.000] after inductionDecreased oxygen at 35 mins [mean SpO2 (SD): 93.14 (4.71) vs 97.0 (1.63), P = 0.002], 40 mins [mean SpO2 (SD): 94.29 (3.94) vs 97.08 (1.13), P = 0.027], and 45 mins [mean SpO2 (SD): 93.92 (4.17) vs 97.42 (1.51), P = 0.048] after induction |
Apan [11] | – | + | midazolam and saline | No statistically significant differences in MAP between groups | Decreased 35–50 min after start of surgery and extending to 15 mins postoperatively [data values not reported, P < 0.05] | No statistically significant differences in respiratory rate or ETCO2h values |
Ayoglu [21] | + | + | no sedation | Decreased arterial pressure up to 30 mins after start of surgery [data values not reported, P < 0.05] | Decreased intraoperative mean HR up to 50 mins after start of surgery [data values not reported, P < 0.05] | No statistically significant differences in SpO2 or respiratory rate reported |
Dogan [13] | + | + | midazolam-fentanyl with topical analgesia or peribulbar block | No statistically significant differences in SBP and DBPi between groups | No statistically significant differences | No statistically significant differences in respiratory rate |
Erdurmus [14] | + | + | saline | No statistically significant differences in SBP and DBP between groups | No statistically significant differences | No statistically significant differences in SpO2 between groups |
Ghodki [15] | + | – | saline | Decreased MAP after premedication [mean MAP (SD): 86.88 (10.75) vs 99.10 (12.36), P = 0.005], intraoperatively [mean MAP (SD): 88.26 (11.03) vs 107.20 (7.90), P = 0.000], and postoperatively [mean MAP (SD): 81.02 (11.10) vs 90.03 (9.24), P = 0.008] | Decreased after premedication [mean HR (SD): 72.42 (13.25) vs 81.4 (7.36), P = 0.005], intraoperatively [mean HR (SD): 76.00 (14.21) vs 89.75 (9.21), P = 0.000], and postoperatively [mean HR (SD): 68.50 (11.54) vs 79.50 (15.68), P = 0.009] | No statistically significant differences in ETCO2 between groups |
Kermany [10] | + | + | remifentanil | Decreased MAP postoperatively [mean MAP (SD): 76.3 (5.4) vs 85.2 (8.6), P = 0.01] | Decreased postoperatively [mean HR (SD): 65.4 (7.6) vs 72.1 (4.5), P = 0.009] | No statistically significant difference in SpO2 between groups |
Muttu [16] | + | + | midazolam | No statistical analyses provided | No statistical analyses provided | No periods of desaturation in either group |
Na [17] | – | + | propofol-alfentanil | Decreased SBP at surgery start [SBP (SD): 117 (16) vs 129 (19), P < 0.05], all intraoperative time points [SBP (SD): 117 (17) vs 129 (18), P < 0.05; 114 (15) vs 127 (18), P < 0.05; 112 (14) vs 126 (15), P < 0.05], and postoperatively [SBP (SD): 107 (15) vs 129 (18), P < 0.05] | No statistically significant differences between groups | No statistically significant difference in respiratory rate or SpO2 between groups |
Park [22] | + | + | remifentanil | Decreased MAP [data values and P values not reported] | No statistically significant differences | Decreased ETCO2 and increased respiratory rate [data values not reported] No statistically significant differences in SpO2 |
Virkilla [19] | + | – | placebo | Decreased SBP in 1.5 mcg/kg group compared to placebo [data values not reported, P < 0.001] | Decreased in 1.5 mcg/kg group compared to placebo [data values not reported, P = 0.004] | No statistically significant changes in SpO2 |
Virkilla [20] | + | – | midazolam and placebo | Decreased SBP and DBP before periocular block compared to placebo [data values not reported, P < 0.001] Decreased SBP [data values not reported, P = 0.003] and DBP [data values not reported, P = 0.009] compared to midazolam before periocular block Decreased mean SBP and DBP compared to midazolam and placebo [data values not reported, P < 0.001] Decreased SBP postoperatively compared to midazolam and placebo [data values not reported, P < 0.001] | Decreased intraoperatively compared to placebo [data values not reported, P < 0.001] and midazolam [data values not reported, P = 0.01]Decreased postoperatively compared to placebo [data values not reported, P < 0.001] | Decreased SpO2 compared to midazolam and placebo before block [data values not reported, P < 0.001] |
Yagan [18] | + | – | ketofolj | Decreased MAP after drug administration and all time points thereafter compared to baseline and ketofol [data values not reported, P < 0.05] | Decreased after drug administration and all time points thereafter compared to baseline [data values not reported, P < 0.05] | No statistically significant difference in respiratory rate |